ClinicalTrials.gg
Not yet recruitingNCT06818604Updated Feb 10, 2025

Comparing CPAP and BiPAP for Sleep-Disordered Breathing in People with Cervical Spinal Cord Injuries

An interventional study of CPAP and BiPAP in Spinal Cord Injuries (SCI), Sleep Disordered Breathing (SDB) and Sleep Apnea, sponsored by University of British Columbia. Not yet recruiting at 1 site in Canada. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-02-10.

Sponsored by University of British Columbia · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 44 studies in Spinal Cord Injuries by University of British Columbia — 16 open to participants now, 18 under way, none of them phase 3. Spinal Cord Injuries · University of British Columbia.

Planned enrollment
11th of 38
32 · median 22
Started
2025
with 1 other
No phase
31 of 44
13 open now
Primary completion
2026-09
later than 6 of 17 live
Registered
38th of 44
by date

Among the 44 studies in Spinal Cord Injuries by University of British Columbia, this one is the 11th largest by planned enrollment of the 38 interventional ones that give a count, is one of 2 that started in 2025, is one of 31 with no phase, reaches primary completion later than 6 of the 17 other live ones, and was the 38th registered.

Spinal Cord Injuries

2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.

Browse Spinal Cord Injuries studies →

Open to participants now

16 of the 44 studies in Spinal Cord Injuries by University of British Columbia are open now, in 2 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

Who these studies take

Of the 374 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 156 (42%) stop at 75 or younger; 40 take children under 18; 52 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Spinal Cord Injuries by University of British Columbia, or all of them as a file.
02

Study summary

Sleep-disordered breathing (SDB) is common in individuals with cervical spinal cord injuries, with studies suggesting prevalence rates ranging from 27% to 62%. The condition often leads to daytime sleepiness, fatigue, and poor participation in rehabilitation. Positive airway pressure therapy can be used to treat the condition; however, some individuals find continuous positive airway pressure (CPAP), which applies the same pressure during inhalation and exhalation, difficult to use. Bilevel positive airway pressure (BiPAP) offers different pressures for inhalation and exhalation, which may be more comfortable and potentially improve adherence in this patient population. However, limited evidence compares CPAP and BiPAP in individuals with cervical spinal cord injuries.

This pilot study will enroll 32 adult participants with cervical spinal cord injuries who have moderate to severe SDB (defined as an AHI of 15 events/hour or greater). Participants will be randomly assigned to either CPAP or BiPAP therapy for 4 weeks. Device usage per night will be measured, and data on daytime sleepiness, fatigue, and sleep quality will be collected at baseline, 2 weeks, and 4 weeks. The investigators aim to determine whether BiPAP improves adherence and symptoms compared to CPAP in this patient population.

03

Conditions studied

  • Spinal Cord Injuries (SCI)
  • Sleep Disordered Breathing (SDB)
  • Sleep Apnea
  • Cervical Spinal Cord Injruy

Keywords

  • sleep disordered breathing
  • Cervical Vertebrae
  • Obstructive Sleep Apnea
  • Spinal Cord Injuries
  • Positive Pressure Respiration
  • Continuous Positive Airway Pressure
  • Sleep Quality
  • Quadriplegia
  • Polysomnography
  • Tetraplegia
  • Sleep Wake Disorders
  • Diaphragmatic Paralysis
  • Autonomic Dysreflexia
  • Muscle Weakness
  • Nocturnal Hypoventilation
  • Phrenic Nerve
  • Pulmonary Atelectasis
  • Spinal Cord Compression
  • Ventilator Weaning
  • Neurological Rehabilitation
  • Sleep Disorders
  • Activities of Daily Living
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >= 19 years
  • Cervical spinal cord injury (ASIA A, B, or C). This will include patients with upper (C1-C4) and lower (C5-C7) spinal cord injuries
  • Presence of sleep disordered breathing, defined as AHI > =15 events/hour by home sleep apnea test (HSAT)

Exclusion criteria

Exclusion Criteria:

  • On CPAP or BiPAP prior to spinal cord injury
  • Hypoventilation syndrome (elevated venous carbon dioxide, PvCO2>50 mm Hg)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    CPAP Therapy

    Device: CPAP

  • Experimental
    BiPAP Therapy

    Device: BiPAP

Interventions

  • DeviceCPAP

    Participants randomized to this group will receive auto-CPAP therapy. The device will be initiated by a respiratory therapist at GF Strong Rehabilitation Centre. Settings will be adjusted to achieve a device efficacy index \< 5 events per hour.

  • DeviceBiPAP

    Participants will receive BiPAP S mode therapy for 4 weeks. The device will be initiated by a respiratory therapist at GF Strong Rehabilitation Centre with initial settings of IPAP 8 cmH2O and EPAP 3 cmH2O. Settings will be modified to a maximum tolerated level to achieve a tidal volume of 8 mL/kg ideal body weight and SpO2 \> 95%. Overnight oximetry will be performed to ensure at least 4 hours of device use, and settings will be adjusted to achieve a DEI \< 5 events per hour.

06

What researchers measure

Primary outcomes

  1. Adherence to PAP Therapy

    Median hours of PAP device use per night, objectively measured via device download. Additional metrics include: % days used \>4 hrs/night, total # of days used, total # of hours used.

    Time frame: 4 weeks

Secondary outcomes

  1. Daytime Sleepiness

    Measured using the Epworth Sleepiness Scale (ESS). ESS is a self-administered questionnaire that asks participants to rate their likelihood of dozing off or falling asleep in eight different situations that are common in daily life. Scores range from 0 to 24, with higher scores indicating greater daytime sleepiness.

    Time frame: 4 weeks

  2. Sleep Quality

    Measured using the Pittsburgh Sleep Quality Index (PSQI). The PSQI is a self-rated questionnaire that assesses sleep quality over the past month. The PSQI yields seven component scores, each ranging from 0 to 3, which are summed to produce a global PSQI score ranging from 0 to 21. Higher global PSQI scores indicate poorer sleep quality.

    Time frame: 4 weeks

  3. Fatigue

    Measured using the PROMIS-Fatigue (PROMIS-F) scale. The PROMIS-F is a standardized, self-reported measure of fatigue. PROMIS-F T-scores are standardized to a mean of 50 and a standard deviation of 10. Higher T-scores indicate greater fatigue.

    Time frame: 4 weeks

  4. PAP side effects

    Assessed using a PAP therapy side effect survey. This survey will collect information about any side effects experienced by participants as a result of using the PAP devices.

    Time frame: 4 weeks

  5. Recruitment Rate

    Helps assess the feasibility of recruiting this specific patient population for future, larger studies. Also helps us understand if there are any barriers to participation that need to be addressed in future research. Recruitment rate will be assessed as the average number of participants enrolled per month during the recruitment period.

    Time frame: 4 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2025; primary completion for Sep 2026, 13 months later.

Of 791 non-industry interventional studies with no phase under Spinal Cord Injuries, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's planned 13 months is below that.

Counting every sponsor, half of 840 studies reached it within 36 months; a quarter within 17 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2025
First posted
Feb 10, 2025
StartEst.
Aug 1, 2025
Primary completionEst.
Sep 1, 2026
CompletionEst.
Sep 1, 2027
Last update
Feb 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06818604
Responsible party
Najib Ayas (Principal Investigator, University of British Columbia) — Principal investigator
First posted
Feb 10, 2025
Start date
Aug 1, 2025 (estimated)
Primary completion
Sep 1, 2026 (estimated)
Completion
Sep 1, 2027 (estimated)
Last update
Feb 10, 2025

Study contacts

Najib Ayas
Contact
nayas@providencehealth.bc.ca
604-875-4122
Viet Vu
Contact
Viet.Vu@vch.ca
604-734-1313

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion